tiprankstipranks
Trending News
More News >

Tryptamine Therapeutics Announces Director’s Interest Changes

Story Highlights
Tryptamine Therapeutics Announces Director’s Interest Changes

Confident Investing Starts Here:

The latest update is out from Tryptamine Therapeutics ( (AU:TYP) ).

Tryptamine Therapeutics Limited has announced a change in the director’s interest, specifically for Jason Carroll, through the allotment of capital raising shares and options. The company has increased its ordinary fully paid shares by 15 million and options by 7.5 million, as approved by shareholders, which reflects a strategic move to bolster its capital structure.

More about Tryptamine Therapeutics

YTD Price Performance: -15.79%

Average Trading Volume: 1,658,752

Technical Sentiment Signal: Buy

Current Market Cap: A$40.85M

For an in-depth examination of TYP stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App